HAS opinions and decisions
La fiche de bon usage du médicament intitulée « Xolair (omalizumab) dans le traitement de l’asthme sévère», ci-jointe, est adoptée.
See also
HAS opinions and decisions
17/11/2017
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
VfHEkEMzP2DrX7BH